schliessen

Filtern

 

Bibliotheken

Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA

Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the mu peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with ex... Full description

Journal Title: Gene therapy May 2002, Vol.9(9), pp.564-76
Main Author: Tagawa, T
Other Authors: Manvell, M , Brown, N , Keller, M , Perouzel, E , Murray, K D , Harbottle, R P , Tecle, M , Booy, F , Brahimi-Horn, M C , Coutelle, C , Lemoine, N R , Alton, E W F W , Miller, A D
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0969-7128 ; PMID: 11973632 Version:1
Link: http://pubmed.gov/11973632
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline11973632
title: Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
format: Article
creator:
  • Tagawa, T
  • Manvell, M
  • Brown, N
  • Keller, M
  • Perouzel, E
  • Murray, K D
  • Harbottle, R P
  • Tecle, M
  • Booy, F
  • Brahimi-Horn, M C
  • Coutelle, C
  • Lemoine, N R
  • Alton, E W F W
  • Miller, A D
subjects:
  • Adenoviridae
  • Genetic Engineering
  • Liposomes
  • Nanotechnology
  • Plasmids
  • Viral Core Proteins
ispartof: Gene therapy, May 2002, Vol.9(9), pp.564-76
description: Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the mu peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 +/- 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80 degrees C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 microg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG(5000) (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.
language: eng
source:
identifier: ISSN: 0969-7128 ; PMID: 11973632 Version:1
fulltext: fulltext
issn:
  • 09697128
  • 0969-7128
url: Link


@attributes
ID940969579
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid11973632
sourceidmedline
recordidTN_medline11973632
sourceformatXML
sourcesystemOther
pqid218714915
display
typearticle
titleCharacterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
creatorTagawa, T ; Manvell, M ; Brown, N ; Keller, M ; Perouzel, E ; Murray, K D ; Harbottle, R P ; Tecle, M ; Booy, F ; Brahimi-Horn, M C ; Coutelle, C ; Lemoine, N R ; Alton, E W F W ; Miller, A D
ispartofGene therapy, May 2002, Vol.9(9), pp.564-76
identifierISSN: 0969-7128 ; PMID: 11973632 Version:1
subjectAdenoviridae ; Genetic Engineering ; Liposomes ; Nanotechnology ; Plasmids ; Viral Core Proteins
descriptionLiposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the mu peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 +/- 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80 degrees C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 microg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG(5000) (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/11973632$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Tagawa, T
1Manvell, M
2Brown, N
3Keller, M
4Perouzel, E
5Murray, K D
6Harbottle, R P
7Tecle, M
8Booy, F
9Brahimi-Horn, M C
10Coutelle, C
11Lemoine, N R
12Alton, E W F W
13Miller, A D
titleCharacterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
descriptionLiposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the mu peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 +/- 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80 degrees C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 microg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG(5000) (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.
subject
0Adenoviridae
1Genetic Engineering
2Liposomes
3Nanotechnology
4Plasmids
5Viral Core Proteins
general
011973632
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline11973632
issn
009697128
10969-7128
rsrctypearticle
creationdate2002
addtitleGene therapy
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41200205
citationpf 564 vol 9 issue 9
startdate20020501
enddate20020531
lsr30VSR-Enriched:[doi, pages, pqid, eissn]
sort
titleCharacterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
authorTagawa, T ; Manvell, M ; Brown, N ; Keller, M ; Perouzel, E ; Murray, K D ; Harbottle, R P ; Tecle, M ; Booy, F ; Brahimi-Horn, M C ; Coutelle, C ; Lemoine, N R ; Alton, E W F W ; Miller, A D
creationdate20020500
lso0120020500
facets
frbrgroupid3994966068475342329
frbrtype5
newrecords20190702
languageeng
creationdate2002
topic
0Adenoviridae
1Genetic Engineering
2Liposomes
3Nanotechnology
4Plasmids
5Viral Core Proteins
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Tagawa, T
1Manvell, M
2Brown, N
3Keller, M
4Perouzel, E
5Murray, K D
6Harbottle, R P
7Tecle, M
8Booy, F
9Brahimi-Horn, M C
10Coutelle, C
11Lemoine, N R
12Alton, E W F W
13Miller, A D
jtitleGene Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Tagawa
1Manvell
2Brown
3Keller
4Perouzel
5Murray
6Harbottle
7Tecle
8Booy
9Brahimi-Horn
10Coutelle
11Lemoine
12Alton
13Miller
aufirst
0T
1M
2N
3E
4K D
5R P
6F
7M C
8C
9N R
10E W F W
11A D
au
0Tagawa, T
1Manvell, M
2Brown, N
3Keller, M
4Perouzel, E
5Murray, K D
6Harbottle, R P
7Tecle, M
8Booy, F
9Brahimi-Horn, M C
10Coutelle, C
11Lemoine, N R
12Alton, E W F W
13Miller, A D
atitleCharacterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA
jtitleGene therapy
risdate200205
volume9
issue9
spage564
pages564-576
issn0969-7128
formatjournal
genrearticle
ristypeJOUR
abstractLiposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the mu peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 +/- 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80 degrees C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 microg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG(5000) (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.
pmid11973632
doi10.1038/sj.gt.3301686
eissn14765462
oafree_for_read
date2002-05